Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Subscribe To Our Newsletter & Stay Updated
